ArticleFrontiers in pharmacology2026
Cost-effectiveness of nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable hepatocellular carcinoma in China: a modeling study with price threshold analysis.
Rui Feng et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.